Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS)

NCT04530604 is registered in ClinicalTrials.gov with Gregory Yanik as lead sponsor.

NCT NCT04530604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04530604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Defibrotide Therapy for SARS-CoV2 Acute Respiratory Distress Syndrome (ARDS)
Lead sponsor
Gregory Yanik
Phase
Phase 1
Overall status
Completed
Start date
October 1, 2020
Completion date
April 9, 2021
Enrollment
13 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, covid, covid-19, sars-cov2